Clifford Chance advised Keymed Biosciences on the deal. Keymed Biosciences (HKSe: 02162) signed a licensing agreement granting Platina the exclusive worldwide rights to develop, manufacture and...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Keymed Biosciences on the deal. Timberlyne Therapeutics, Inc. announced its US$180 million Series A financing to advance the development of CM313. Investors Abingworth,...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Sanofi on the deal. Global healthcare company Sanofi announced the acquisition of exclusive rights to develop and commercialise aficamten in Greater China from...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Sanofi on the deal. Global healthcare company Sanofi announced the acquisition of exclusive rights to develop and commercialise aficamten in Greater China from...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Fosun Kairos Biotechnology Co., Ltd. on the deal. Fosun Kairos Biotechnology Co., Ltd. (Fosun Kairos) signed its license agreement with Kite Pharma...
You must be a Standard 1 Year member to access this content.
On the deal, Clifford Chance and Mourant advised CBC Group and Mubadala; Cleary Gottlieb acted as onshore legal advisors to Mubadala. CBC Group, Asia’s largest healthcare-dedicated...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Keymed Biosciences (Chengdu) Co., Ltd. on the deal. Keymed Biosciences (Chengdu) Co., Ltd. completed an out-licensing transaction with Belenos Biosciences, Inc.to exclusively...
You must be a Standard 1 Year member to access this content.
